Cerium oxide nanoparticles in cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 835-840

  Gao, Ying ^a   Chen, Kan ^b   Ma, Jin Lu ^a   Gao, Fei ^c  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer treatment; Cerium oxide nanoparticles; Radioprotection; Radiosensitization

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CERIUM OXIDE; CURCUMIN; CYTOCHROME C; MANGANESE SUPEROXIDE DISMUTASE; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; PH; PROTEIN EXPRESSION; RADIATION PROTECTION; RADIOSENSITIZATION; REVIEW;

EID: 84901499451     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/ott.s62057     Document Type: Review

References (74)

1. Wang Y, Zi XY, Su J, et al. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. Int J Nanomedicine. 2012;7: 2641-2652.
2. Yang F, Tang Q, Zhong X, et al. Surface decoration by Spirulina polysac- charide enhances the cellular uptake and anticancer effcacy of selenium nanoparticles. Int J Nanomedicine. 2012;7:835-844.
3. Lee P, Zhang R, Li V, et al. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine. 2012;7:731-737.
4. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA. 2008;105:9343-9348.
5. Siddiqui IA, Adhami VM, Chamcheu JC, Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomedicine. 2012;7:591-605.
6. Ghadiali JE, Cohen BE, Stevens MM. Protein kinase-actuated reso- nance energy transfer in quantum dot - peptide conjugates. ACS Nano. 2010;4:4915-4919.
7. Wason MS, Zhao J. Cerium oxide nanoparticles: potential applications for cancer and other diseases. Am J Transl Res. 2013;5:126-131.
8. Lee SK, Kim GS, Wu Y, et al. Nanowire substrate-based laser scan- ning cytometry for quantitation of circulating tumor cells. Nano Lett. 2012;12:2697-2704.
9. Dicheva BM, ten Hagen TL, Li L, et al. Cationic thermosensitive lipo- somes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells. Nano Lett. 2013;13:2324-2331.
10. Kanapathipillai M, Mammoto A, Mammoto T, et al. Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. Nano Lett. 2012;12:3213-3217.
11. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine. 2013;8:61-71.
12. Wang Y, Yang F, Zhang HX, et al. Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis. 2013;4:e783.
13. Asati A, Santra S, Kaittanis C, Nath S, Perez JM. Oxidase-like activity of polymer-coated cerium oxide nanoparticles. Angew Chem Int Ed Engl. 2009;48:2308-2312.
14. Korsvik C, Patil S, Seal S, Self WT. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem Commun (Camb). 2007;14:1056-1058.
15. Pirmohamed T, Dowding JM, Singh S, et al. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem Commun (Camb). 2010;46:2736-2738.
16. Dowding JM, Dosani T, Kumar A, Seal S, Self WT. Cerium oxide nanoparticles scavenge nitric oxide radical (̇NO). Chem Commun (Camb). 2012;48:4896-4898.
17. Xue Y, Luan QF, Yang D, Yao X, Zhou K. Direct evidence for hydroxyl radical scavenging activity of cerium oxide nanoparticles. J Phys Chem C Nanomater Interfaces. 2011;115:4433-4438.
18. Asati A, Santra S, Kaittanis C, Perez JM. Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano. 2010;4:5321-5331.
19. Wason MS, Colon J, Das S, et al. Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine. 2013,9:558-569.
20. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006;5:14.
21. Ray PD, Huang B W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981-990.
22. Rzigalinski BA, Meehan K, Davis RM, Xu Y, Miles WC, Cohen CA. Radical nanomedicine. Nanomedicine (Lond). 2006;1:399-412.
23. Park EJ, Choi J, Park YK, Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology. 2008;245:90-100.
24. Dam DH, Lee JH, Sisco PN, et al. Direct observation of nanoparticle- cancer cell nucleus interactions. ACS Nano. 2012;6:3318-3326.
25. Ma X, Zhang LH, Wang LR, et al. Single-walled carbon nanotubes alter cytochrome c electron transfer and modulate mitochondrial function. ACS Nano. 2012;6:10486-10496.
26. Huanga JG, Leshuk T, Gu FX. Emerging nanomaterials for targeting subcellular organelles. Nano Today. 2011;6:478-492.
27. Wang L, Liu Y, Li W, et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett. 2011;11:772-780.
28. Alili L, Sack M, Karakoti AS, et al. Combined cytotoxic and anti- invasive properties of redox-active nanoparticles in tumor-stroma interactions. Biomaterials. 2011;32:2918-2929.
29. Desmoulière A, Guyot C, Gabbiani G. The stroma reaction myofbro- blast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48:509-517.
30. Papakostidi A, Tolia M, Tsoukalas N. Quality assurance in Health Services: the paradigm of radiotherapy. J BUON. 2014;191:47-52.
31. Sveistrup J, Af Rosenschöld PM, Deasy JO, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radio- therapy without daily image guidance. Radiat Oncol. 2014;9:44.
32. Citrin D, Cotrim A P, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist. 2010;15:360-371.
33. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective- target and broad-spectrum radioprotector. Oncologist. 2007;12:738-747.
34. Colon J, Hsieh N, Ferguson A, et al. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine. 2010;6:698-705.
35. Colon J, Herrera L, Smith J, et al. Protection from radiation-induced pneumonitis using cerium oxide nanoparticles. Nanomedicine. 2009;5: 225-231.
36. Tarnuzzer RW, Colon J, Patil S, Seal S. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett. 2005;5:2573-2577.
37. Madero-Visbal RA, Alvarado BE, Colon JF, et al. Harnessing nanopar- ticles to improve toxicity after head and neck radiation. Nanomedicine. 2012;8:1223-1231.
38. Dahle JT, Livi K, Arai Y. Effects of pH and phosphate on CeO2 nano- particle dissolution. Chemosphere. Epub March 11, 2014.
39. Arita T, Yoo J, Ueda Y, Adschiri T. Size and size distribution balance the dispersion of colloidal CeO2 nanoparticles in organic solvents. Nanoscale. 2010;2:689-693.
40. Das S, Singh S, Dowding JM, et al. The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials. 2012;33:7746-7755.
41. Lord MS, Tsoi B, Gunawan C, Teoh WY, Amal R, Whitelock JM. Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles. Biomaterials. 2013;34:8808-8818.
42. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simul- taneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009;136:21-29.
43. Kabanov AV, Batrakova E V, Alakhov VY. Pluronic block copoly- mers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002;54:759-779.
44. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikap- paBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101:1053-1062.
45. Jobin C, Bradham CA, Russo M P, et al. Curcumin blocks cytokine- mediated NF-kappa B activation and proinfammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;163:3474-3483.
46. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008;14:2128-2136.
47. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008;267:133-164.
48. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376-383.
49. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007;13:3423-3430.
50. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits prolifera- tion, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47:293-303.
51. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199-225.
52. van't Land B, Blijlevens NM, Marteijn J, et al. Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. 2004;18:276-284.
53. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi B V, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett. 1999;456:311-314.
54. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005;223:181-190.
55. Mitchell TM Somasundaram, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62:3868-3875.
56. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62: 3868-3875.
57. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of cur- cumin and 5-fuorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy. 2006;52:23-28.
58. Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fuorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008;122:267-273.
59. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998;17:173-178.
60. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
61. Lao CD, Ruffn MT, Normolle D, et al. Dose escalation of a cur-cuminoid formulation. BMC Complement Altern Med. 2006;6:10.
62. Bisht K, Wagner KH, Bulmer AC. Curcumin, resveratrol and favonoids as anti-infammatory, cyto- and DNA-protective dietary compounds. Toxicology. 2010;278:88-100.
63. Shutava TG, Balkundi SS, Vangala P, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano. 2009;3:1877-1885.
64. Shieh YA, Yang SJ, Wei M F, Shieh MJ. Aptamer-based tumor tar- geted drug delivery for photodynamic therapy. ACS Nano. 2010;4: 1433-1442.
65. Wang T, He N. Preparation, characterization and applications of low- molecular-weight alginate-oligochitosan nanocapsules. Nanoscale. 2010;2:230-239.
66. He N, Wang T, Jiang L, Wang D, Hu Y, Zhang L. Therapy for cerebral ischemic injury with erythropoietin-containing nanoparticles. J Nanosci Nanotechnol. 2010;10:5320-5323.
67. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97-110.
68. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-infammatory properties of cerium oxide nanoparticles. Small. 2009;5:2848-2856.
69. Singh S, Kumar A, Karakoti A, Seal S, Self WT. Unveiling the mecha- nism of uptake and sub-cellular distribution of cerium oxide nanopar- ticles. Mol Biosyst. 2010;6:1813-1820.
70. Zhou X, Wong LL, Karakoti AS, Seal S, McGinnis JF. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse. PLoS One. 2011;6:e16733.
71. Clark A, Zhu A, Sun K, Petty HR. Cerium oxide and platinum nanopar- ticles protect cells from oxidant-mediated apoptosis. J Nanopart Res. 2011;13:5547-5555.
72. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol. 2006;1:142-150.
73. Xia T, Kovochich M, Liong M, et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolu- tion and oxidative stress properties. ACS Nano. 2008;2:2121-2134.
74. Lin W, Huang Y W, Zhou XD, Ma Y. Toxicity of cerium oxide nanopar- ticles in human lung cancer cells. Int J Toxicol. 2006;25:451-457.